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Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States.
There has not been a new SLE drug approved in the United States since 1958. However, a guidance document
issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numer-
ous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator,
met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents
targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest
therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.
Introduction
Systemic lupus erythematosus (SLE, commonly referred
to as lupus) is a pleomorphic, autoimmune disorder of
unknown cause. Afflicting approximately 500,000 people
in the United States, SLE is characterized by consider-
able mortality and morbidity. For example, with existing
therapies, half of patients with organ-threatening disease
(for example, cardiopulmonary, hepatic, renal, central
nervous system or autoimmune hemolytic anemia) do
not survive 20 years after diagnosis, and the quality of
life for those individuals with all forms of SLE is usually
seriously compromised [1]. To date, the only agents
approved by the Food and Drug Administration (FDA)
for SLE are corticosteroids, antimalarials and aspirin,
with hydroxychloroquine being the most recent addition
to this armamentarium (in 1958). Now, developments in
our understanding of the underlying pathogenesis of
SLE have led to promising new leads for SLE drug
therapy.
SLE drug development was stunted by SLE’sb e i n ga
“woman’s disease,” inadequate SLE advocacy and mostly
by the National Institutes of Health nephritis trial that
ran for 20 years in the 1970 s and 1980 s, which demon-
strated that a mean time of 5 years elapsed before a treat-
ment arm (intravenous cyclophosphamide versus
azathioprine, prednisone alone, or a combination oral
cyclophosphamide plus azathioprine) was found to be
superior [2]. Not being that patient, the pharmaceutical
industry invested its rheumatic disease resources into the
rheumatoid arthritis (RA) and spondylitis pipeline, where
outcomes were evident within 3-6 months. In 2005, the
Federal Register published a guidance document (fina-
lized in 2010) aimed at investigators and industry that
provided a roadmap detailing what a SLE trial would
need to demonstrate to shepherd a new agent to market
[3]. This led to the launches of a number of trials. Many
errors were made by experienced lupologists (myself
included) who were new to the art of clinical trial design.
This included giving both arms of a study effective treat-
ment, including patients whose diagnosis of SLE was
dubious, overestimation of flare rates resulting in under-
powered studies, failure to guarantee adequate supply of
a drug, faulty infusion directions, underdosing effective
drugs for financial reasons and overestimating steroid
requirements. This minireview critically analyzes the
current state of the art in SLE drug development from a
regulatory and implementation standpoint.
Ground rules: Requirements for a new SLE drug
The June 2010 FDA guidelines indicate that a candidate
SLE drug should meet its primary endpoint in two ade-
quate well-controlled trials demonstrating superiority [4].
Studies should be at least 1 year in duration, and enrol-
lees should fulfill the American College of Rheumatology
criteria for SLE. Steroid use variability should be mini-
mized, and sparing effects, if any, should be defined.
Study patients should be stratified by the severity of their
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(BILAG) 2004 [5] guidelines being the preferred index
for measuring disease reduction (although the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI),
European Community Lupus Activity Measure (ECLAM)
and Systemic Lupus Activity Measure (SLAM) are also
acceptable). The document provides definitions for par-
tial clinical response, remission, reduction in flare and
increase in time to flare; encourages the use of patient-
reported outcome measures; and leaves the door open
for biomarkers and surrogate markers (none of the cur-
rent ones being acceptable) potentially applicable to
shorten the duration of a trial as well as improving our
measurement of disease activity. Any agent must demon-
strate a satisfactory safety profile, and the document sup-
ports the use of organ-specific measures (for example,
the Cutaneous Lupus Activity Disease Area and Severity
Index (CLASI) for cutaneous disease), especially if the
drug is efficacious for one aspect of the disease but not
another. The 2010 guidance document takes into account
“lessons learned” and nuances that make SLE drug devel-
opment so complex.
The use of nontargeted agents: Important recent studies
The overwhelming majority of agents in development
are biologics. However, some nonbiological agents and
drugs that are on the market for other disorders have
been or are under study for SLE. A detailed discussion
of these studies is beyond the scope of this minireview,
but the salient points are summarized below:
1. Fish oil is ameliorative in patients with mild activity [6].
2. A large trial evaluating the efficacy of vitamin D is
in progress (NCT 00418507).
3. The Canadian Cooperative Consortium recently
demonstrated that methotrexate is steroid sparing and
has anti-inflammatory properties [7].
4. Mycophenolate mofetil is equivalent to cyclopho-
sphamide as induction therapy for SLE nephritis and is
superior to azathioprine for maintenance [8,9].
5. Topical pinecrolimus and tacrolimus are effective
for chronic cutaneous SLE [10].
6. Leflunomide improves SLE arthritis [11].
7. Dehydroepiandrostrone has modest effects at best in
mild SLE and may diminish fatigue and bone deminerali-
zation, as well as having steroid sparing properties [12].
In summary, none of the above agents are significantly
ameliorative of SLE, and none have been shown to sig-
nificantly influence its morbidity or mortality when
compared to other agents currently available.
Targeted therapies and SLE: Current status
Multiple mechanisms of action are being explored in a
variety of targeted therapies. They are summarized in
Table 1.
Immune cell-specific targets (B and T cells)
Inhibition of T cell activation and blockade of the costi-
mulatory pathway is a promising approach (Table 2).
Abatacept, already approved for RA, appears to improve
musculoskeletal SLE and has an excellent safety profile
[13]. The sponsor’s choice to frontload their pivotal trial
with a forced steroid taper before the agent reached its
maximal efficacy was unfortunate and led to the primary
endpoint not being met. Bristol-Myers Squibb and the
Immune Tolerance Network have nephritis trials in pro-
gress, and a new phase III trial for musculoskeletal SLE is
planned. Blockade of the CD40L pathway was successful
but not safe with BG9588 (because of thrombotic compli-
cations) and safe but not effective for IDEC [14,15]. New
Table 1 Targets for new therapies in systemic lupus
erythematosus
a
Mechanism of action Examples of targets
T cells CTLA4-Ig, modified CD40L, inhibition of
ICOS
Regulatory T cells: expanding CD4+CD25+,
CD8+CD28-
B cells mAbs to CD20, CD22, BlyS, TACi-Ig, BAFF-
RFc
Proteosome/plasma cells
Cytokines Inhibition of IL-6, IL-10; TNF inhibitors
Innate immune system Inhibition of IFN-a and IFN-g, blockade of
TLR-7 and/or TLR-9, C5a inhibition
Toleragens Peptides derived from nucleosomes,
splicosomes
Cell surface receptor
activation inhibition
Syk kinase, sirolimus
aICOS, ; mAbs, monoclonal antibodies; BlyS, B lymphocyte stimulation; TACi-Ig,
immunoglobulin; BAFF-RFc, ; TNF, tumor necrosis factor; IFN, interferon; TLR,
Toll-like receptor.
Table 2 Important agents currently enrolling patients in
clinical trials for systemic lupus erythematosus as of
November 2010
Target Trial Comment
T cells NCT007744752 Abatacept
NCT00774943 Amgen 557 ICOS inhibitor
B cells NCT00660881 Epratuzumab (anti-CD22)
NCT00624338 Atacicept blocks BlyS and APRIL
NCT01162681 A-623 blocks BlyS and APRIL
NCT01205348 LY2127399 blocks BlyS
Toleragen NCT01085097 Laquinomod
NCT01135459 Lupuzor tolerizes splicosome
Innate immunity NCT00962832 Rontalizumab inhibits IFN-a
NCT01164917 Amgen 811 targets IFN-g
NCT00960362 NNCO152 targets IFN-a
NCT01031836 MEDI-545 targets IFN-a
Cell surface receptor NCT0077194 Rapamycin targets mTOR
aICOS, ; BlyS, B lymphocyte stimulation; APRIL, ; mTOR (mammalian target of
rapamycin).
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pathway are being studied. Amgen 557 is an ICOS-B7-
RP1 (Inducible Costimulator B7-RPI are receptor sites)
inhibitor under evaluation in a phase II trial. Efalizumab,
an LFA-1 inhibitor (Lymphocyte function associated
Antigen-1), was withdrawn from the market in 2010
because of concerns with progressive multifocal leukoen-
cephalopathy, and its cutaneous SLE trial was suspended.
A phase I safety study of an agent which promotes T reg-
ulatory cells (Treg) has been presented [16].
B cell depletion via the anti-CD20 rituximab (Roche,
Basel, Switzerland) was not successful in EXPLORER
or LUNAR “generalized lupus” or nephritis-specific
designed studies where all patients were given high
doses of corticosteroids and immune suppressives as
well [17,18]. Case series clearly suggest that rituximab
ameliorates hemolytic anemia, thrombocytopenia, arthri-
tis and probably central nervous system vasculitis asso-
ciated with SLE. Trials with humanized anti-CD20 s (for
example, ocrelizumab (Roche), Trubion’s (Trubion, Seat-
tle, WA, USA) small molecule immunopharmaceutical,
or SMIP (Small Molecular Immunopharmaceutical);
(Pfizer, New York, NY, USA) were halted for economic,
safety or design reasons, and none are in progress at
this time. Anti-CD22 is a less potent B cell depletor that
internalizes cell signaling promoting proinflammatory
actions. A phase II dose ranging and safety study with
epratuzumab (UNIM Chemique Belge (UCB), Belgium,
Brussles) showed significant improvements in BILAG
scores, and a phase III trial will start in late 2010 [19].
Belimumab (Human Genome Sciences, (Rockville,
MD, USA)/Glaxo Smith Kline, (Uxbridge, UK) is a fully
human monoclonal antibody that selectively targets and
inhibits soluble B lymphocyte stimulation (BLyS), result-
ing in autoreactive B cell apoptosis. Using an FDA-
endorsed responder index that includes improvement in
the Systematic Lupus Erythematosus Disease Activity
Scale (SLEDAI) score, no new BILAG organ system
occurrences and no worsening in physician assessments,
phase II and phase III trials significantly met this end-
point among over 3,000 treated patients that resulted in
an application for approval to the FDA in June 2010
[20-22]. BLyS and A Proliferatiave Inducing Ligand
(APRIL) are ligands for receptors BAFF-R (B Cell Acti-
vation Factor), BCMA (B Cell Maturation Associate)
and TACI(Transmembrane Activator and Calcium
Reproducing Initiator). Agents blocking these compo-
nents in addition to BlyS (or inhibiting membrane BlyS
in addition to soluble BlyS) are being studied. These
include LY2127399 (Lilly), atacicept (in phase III trials;
Merck-Serono), BR-3Fc blockade (Biogen, Cambridge,
MA, USA) and A-623 (Amgen/Anthera, Hayward, CA,
USa). As with belimumab, these drugs primarily target
developing B cells and have minimal actions on the
b o n em a r r o wo rp l a s m ac e l l s . Bortezomib and carfilzu-
mib are small-molecule inhibitors used for multiple
myeloma. These agents block plasma cells, and SLE clin-
ical trials are on the drawing board.
In summary, agents which block the action of T and B
cells are already being used off-label for SLE, and several
drugs in development will probably be available within
the next few years.
Anti-inflammatory targets: Anti-TNF, cytokines, toleragens
and cell surface receptor inhibition
Many patients with RA who have SLE overlap disease
have been treated with anti tumor necrosis factor pro-
ducts [23]. Only infliximab has been studied to any
extent in pure SLE. Synovitis can be helped, but extra-
articular manifestations may worsen and anti-DNA,
anticardiolipin levels can appear or increase.
Anakinra (anti-IL-1Ra) is not effective for SLE, but
tociluzumab (an anti-IL6) was quite potent in a 16-
patient open label phase I trial at the National Institutes
of Health [24]. An anti-interleukin (IL)-6 (CNTO 136;
Johnson & Johnson, New Brunswick, NJ, USA/Centocor,
Horsham, PA, USA) nephritis trial is due to start in late
2010. IL-10 can have favorable or unfavorable effects in
SLE because of its pleomorphic properties; however, a
favorable phase I safety trial of an anti-IL-10 (Schering,
Berlin, Germany) is not likely to lead to further develop-
ment because of its numerous contradictory actions.
Promising strategies in murine SLE include inhibition of
IL-12, -17, -18, -21 and -23, which may have translatable
effects in humans.
La Jolla Pharmaceutics (La Jolla, CA, USA) LJP394
(Riquent) was an anti-anti-DNA B cell toleragen and
edratide (TEVA, Petach Tikva, Isreal) a toleragen to the
anti-16/6 anti-DNA idiotype [25,26]. Both were safe in
trials involving hundreds of patients, but neither was
effective enough to warrant further investigation. Laqui-
nomod ( TEVA) has been tested in over 3,000 patients
with multiple sclerosis and inflammatory bowel disease
a n da p p e a r st os h i f tT h 1t oT h 2 .A na r t h r i t i sa n d
nephritis trial was begun in late 2010. Lupuzor (Cepha-
lon, Frazer, PA, USA) is a splicosomal peptide with U1
snRNP that promotes tolerance by preventing the prolif-
eration of CD4+ T cells, as well as promoting secretion
of IL-10 and decreasing anti-DNA in a European study.
A phase IIb study is in progress.
Syk kinase inhibits intracellular kinases, and its clinical
efficacy was demonstrated with R788 (Rigel, South San
Francisco, CA, USA) in phase III RA trials [27]. There
are plans to study this agent in SLE. Sirolimus (rapamy-
cin) binds the regulatory kinase mTOR and is used for
renal transplant rejection prevention. Many SLE patients
with transplants currently take this agent, and a phase II
trial is in progress.
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Monoclonal antibodies to C5a were studied and shown to
be safe in a phase I trial a decade ago with eculizumab
(Solaris/Alexion, Cheshire, CT, USA), an agent now
available for paroxysmal nocturnal hemoglobinuria [28].
A newer preparation from Novo Nordisk (Novo Nordisk,
Bagsvaard, Denmark). had its SLE trial halted due to con-
cerns relating to neutropenia in control patients.
Toll-like receptors (TLRs)-7 and -9 in immature dendri-
tic cells are activated by complexes of self-protein and
RNA or DNA. These complexes are normally rapidly
cleared but accumulate in SLE because of clearance
defects. TLR-7 and -9 activation induces secretion of inter-
ferons and promotes inflammation. Antimalarial drugs
target TLR-7 and -9, and the development of a small oral
molecule with similar actions has generated great interest
from several companies (for example, ESAI (Woodcliff
Lake, NJ, USA), Coley (Dusseldorff, Germany)/Xiphon
(New Castle, Delaware, USA)/Pfizer (New York, NY,
USA)). Medi-545 (sifalimumab; Medimmune (Gaithers-
burg, MDm USA)/Astra Zeneca (Wilmington, DE, USA))
and rontalizumab (Roche) can decrease the a-interferon
signature within days by 90% by looking at protein and
gene expression and clear lesions in serial skin biopsies in
phase I studies [29,30] (Table 2). They are currently in
phase III trials. NNC0152 (Novo Nordisk) and Neovasc
are further behind in development, as is an agent which
targets g-interferon (AMG 811; Amgen).
Summary and Conclusions
Providing industry with a guidance document has revolu-
tionized SLE clinical trial development. It is likely that
the first SLE drug to be approved in over 50 years will be
marketed in 2011. Numerous other promising
approaches are being considered that will improve the
morbidity, mortality and quality of life of patients with
SLE. These agents may decrease or make unnecessary the
use of toxic agents such as steroids or immune suppres-
sive agents. The above approaches will influence mild
and organ-threatening disease, as well as having niche
properties translatable into clinically relevant outcomes.
Competing interests
Dr Wallace has performed clinical trials and/or consulted for Biogen, Amgen,
Bristol-Myers Squibb, Roche, Cephalon, UCB, Merck/Serono, Novo Nordisk,
Alexion, Centocor, Esai, TEVA, Rigel, Human Genome Sciences and Lilly.
Received: 29 July 2010 Accepted: 29 November 2010
Published: 29 November 2010
References
1. Wallace DJ, Hahn BH, (Eds): Dubois’ Lupus Erythematosus. 7 edition.
Philadelphia: Lippincott Williams & Wilkins; 2007.
2. Decker JL, Steinberg AD, Reinertsen JL, Plotz PH, Balow JE, Klippel JH: NIH
conference: systemic lupus erythematosus: evolving concepts. Ann Intern
Med 1979, 91:587-604.
3. U.S. Food and Drug Administration: Guidance for Industry on Systemic Lupus
Erythematosus: Developing Drugs for Treatment [http://www.fda.gov/ohrms/
dockets/dockets/05d01-6/05d0106.htm], Accessed July 28, 2010. Also
available at Federal Register 70(59):15868, March 29, 2005.
4. U.S. Food and Drug Administration: Guidance for Industry on Systemic Lupus
Erythematosus: Developing Medical Products for Treatment [http://www.fda.
gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.
htm], Accessed July 28, 2010.
5. Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A,
Bruce IN, Griffiths B, Akil M, McHugh N, D’Cruz D, Khamashta MA,
Bowman S, Maddison P, Zoma A, Allen E, Gordon C, British Isles Lupus
Assessment Group: Revised British Isles Lupus Assessment Group 2004
index: a reliable tool for assessment of systemic lupus erythematosus
activity. Arthritis Rheum 2006, 54:3300-3305.
6. Wright SA, O’Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM,
Johnston DG, Finch MB, Bell AL, McVeigh GE: A randomised interventional
trial of omega-3-polyunsaturated fatty acids on endothelial function and
disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008,
67:841-848.
7. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M,
Canadian Network for Improved Outcomes in Systemic Lupus: Steroid-
sparing effects of methotrexate in systemic lupus erythematosus: a
double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008,
59:1796-1804.
8. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS,
Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus
Management Study Group: Mycophenolate mofetil versus
cyclophosphamide for induction treatment of lupus nephritis. J Am Soc
Nephrol 2009, 20:1103-1112.
9. Wofsy D, Appel GB, Dooley MA, Ginzler EM, Isenberg D, Jayne D,
Solomons N, Lisk L: Aspreva Lupus Management Study maintenance
results. Lupus 2010, 19(Suppl):27.
10. Lampropoulos CE, D’Cruz DP: Topical calcineurin inhibitors in systemic
lupus erythematosus. Ther Clin Risk Manag 2010, 6:95-101.
11. Remer CF, Weisman MH, Wallace DJ: Benefits of leflunomide in systemic
lupus erythematosus: a pilot observational study. Lupus 2001, 10:480-483.
12. Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM,
Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA,
Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD,
Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L,
Ahmed M, Quarles B, Schwartz KE: Effects of prasterone on bone mineral
density in women with active systemic lupus erythematosus receiving
chronic glucocorticoid therapy. J Rheumatol 2008, 35:1567-1575.
13. Merrill JT, Burgos-Varagas R, Westhovens R, Chalmers A, D’Cruz D,
Wallace DJ, Bae SC, Sigal L, Becker JC, Raphupathi K, Peng LT, Kinasczuk M,
Nash P: The efficacy and safety of abatacept in patients with non-life-
threatening manifestations of SLE: results of a 12-month exploratory
study. Arthritis Rheum 2010, 62:377-387.
14. Boumpas DR, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, Vaishnaw A: A
short course of BG9588 (anti-CD 40 ligand antibody) improves serologic
activity and decreases hematuria in patients with proliferative lupus
glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
15. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus
Study Group: Treatment of systemic lupus erythematosus by inhibition
of T cell costimulation with anti-CD154: a randomized, double-blind,
placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
16. Czeloth N, Dalken B, Engling A, Osterroth F, Aigner S, Abufarag A,
Wartenberg-Demand A, Koch H, Becker C, Jonuleit H, Daniel V, Haefeli WE,
Schwarz A, Hass J, Wildemann B, Uherek C: Selective activation of
naturally occurring T cells (Tregs) by the monoclonal antibody BT-061 as
a novel therapeutic opportunity: preclinical and early clinical results.
Annals Rheum Dis 2010, 69(S1):99.
17. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC,
Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy
and safety of rituximab in moderately-to-severely active systemic lupus
erythematosus. Arthritis Rheum 2010, 62:222-233.
18. Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J,
Fervenza FC, Maciuca R, Brunetta P, Zhang D, Garg J: Efficacy and safety of
rituximab in subjects with active proliferative lupus nephritis (LN):
results from the randomized, double-blind phase III LUNAR study.
Arthritis Rheum 2009, 60:S429.
Wallace BMC Medicine 2010, 8:77
http://www.biomedcentral.com/1741-7015/8/77
Page 4 of 519. Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon C:
Epratuzumab demonstrates clinically meaningful improvements in
patients with moderate to severe systemic lupus erythematosus (SLE):
results from EMBLEM, a phase IIb study. Annals Rheum Dis 2010, 69(Suppl
3):558.
20. Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merrill JT, Petri MA,
Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR,
Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-
controlled, dose-ranging study of belimumab in patients with active
systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178.
21. Navarra S, Ilianova E, Bae SC, Guzman R, Tanasescu C, Gallacher A, Levy RA,
Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan J, Kim HY, Pineda L,
Zhong Z, Freimuth W, Petri M, BLISS-52 Study Group: Belimumab, a BlyS-
specific inhibitor reduced disease activity, flares and steroid use in
patients with seropositive systemic lupus erythematosus (SLE): BLISS-52
study. Annals Rheum Dis 2010, 69(S1).
22. Furie RA, Gladman D, d’Cruz D, Zamani O, Wallace D, von Vollenhoven R,
Tegzova D, Merrill JT, Schwarting A, Clarke AE, Doria AE, Sanchez-Guerrero J,
Chatham WW, Manzi S, Ginzler E, Mc Kay J, Stohl W, Zhong ZJ, Hough D,
Cooper SM, Freimuth W, Petri M, Belimumab : A BLyS specific inhibitor,
reduced disease activity and severe flares with seropositive SLE: BLISS-
76 study. Lupus 2010, 19S:13.
23. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G,
Smolen JS: Adverse events and efficacy of TNF-α blockade with
infliximab in patients with systemic lupus erythematosus: long-term
follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454.
24. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T,
Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: data
on safety, preliminary efficacy, and impact on circulating plasma cells
from an open-label phase I dosage-escalation study. Arthritis Rheum 2010,
62:542-552.
25. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, LJP 394-90-
09 Investigator Consortium: Abetimus sodium for renal flare in systemic
lupus erythematosus: results of a randomized, controlled phase III trial.
Arthritis Rheum 2008, 58:2470-2480.
26. Teva Pharmaceutical Industries Ltd.: Press release September 19, 2007.
[http://www.tevapharm.com/pr/2007/pr_689.asp], Accessed July 28, 2010.
27. Weinblatt M, Kavanaugh A, Genovese M, Grossbard E, Magilavy D:
Treatment of rheumatoid arthritis (RA) with an oral syk kinase inhibitor:
A 6 month randomized placebo controlled phase 2b study in patients
with active RA on chronic methotrexate. American College of
Rheumatology 2009 annual scientific meeting, Abstract LB2 [http://acr.confex.
com/acr/2009/webprogram/Paper17160.html], Accessed November 17,
2010.
28. Kaplan M: Eculizumab (Alexion). Curr Opin Investig Drugs 2002, 3:1017-1023.
29. Wallace DJ, Petri M, Olsen N, Kyriou K, Dennis G, Yao Y, Jallal B, Coyle A,
Zeng L, White B: MEDI-545, an anti-interferon α monoclonal antibody,
shows evidence of clinical activity in systemic lupus erythematosus.
Arthritis Rheum 2007, 56:S526.
30. Mc Bride J, Wallace DJ, Morimoto AY, Zhenling Y, Abbas A, Romeo M,
Jiang J, Drappa J: Safety and pharmacodyamic response with
administration of single and repeat doses of rontiluzmab in a phase I,
placebo, controlled, double-blind, dose escalation study in SLE. Lupus
2010, 19S:15.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/8/77/prepub
doi:10.1186/1741-7015-8-77
Cite this article as: Wallace: Advances in drug therapy for systemic
lupus erythematosus. BMC Medicine 2010 8:77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wallace BMC Medicine 2010, 8:77
http://www.biomedcentral.com/1741-7015/8/77
Page 5 of 5